Robert W. Baird Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics (NASDAQ:DFTX) had its price objective lifted by Robert W. Baird from $37.00 to $57.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 55.44% from the company’s previous close.

Several other brokerages also recently issued reports on DFTX. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research note on Monday. Needham & Company LLC raised their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday. Piper Sandler restated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Wolfe Research began coverage on shares of Definium Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $46.08.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $36.67 on Tuesday. The firm has a market cap of $3.66 billion, a price-to-earnings ratio of -14.73 and a beta of 2.37. The company’s fifty day moving average is $22.98 and its 200-day moving average is $18.58. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a 12 month low of $6.34 and a 12 month high of $39.16.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities analysts expect that Definium Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Trading of Definium Therapeutics

Large investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its holdings in Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the last quarter. Creative Planning increased its position in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after buying an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after purchasing an additional 2,342 shares during the period. Rhumbline Advisers raised its holdings in Definium Therapeutics by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after buying an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the period. Institutional investors own 27.91% of the company’s stock.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Phase 3 Emerge data for DT120 were positive, with the study meeting the primary endpoint and all key secondary efficacy endpoints in major depressive disorder. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
• Positive Sentiment: Investors are also reacting to reports that the drug showed “best-case” late-stage results, suggesting meaningful commercial potential if the data hold up in full analysis and regulatory discussions. Definium’s LSD-based pill reduces depression symptoms in late-stage trial
• Neutral Sentiment: The company said it will host a webcast to discuss the results, which could provide more detail on efficacy, safety, and next steps for DT120. Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could dilute existing shareholders even as the stock benefits from the trial win. Definium Therapeutics, Inc. Announces Proposed Public Offering

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.